As the PCa stem cell is described to be a CD133, α2β1, and CD44 positive cell, future studies will need to examine whether SEMA3C is capable of also upregulating expression of CD133 and α2β1. The gene discussed is SEMA3C; the disease is posterior cortical atrophy.